VectivBio Holding AG
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- $1.06 billion
- Book Value:
- Revenue TTM:
- $27.34 million
- Operating Margin TTM:
- Gross Profit TTM:
- $27.34 million
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
VectivBio Holding AG had its IPO on 2021-04-08 under the ticker symbol VECT.
The company operates in the Healthcare sector and Pharmaceuticals industry. VectivBio Holding AG has a staff strength of 0 employees.
Shares of VectivBio Holding AG opened at $16.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $16.85 - $16.85, and closed at $16.85.
This is a 0% increase from the previous day's closing price.
A total volume of 0 shares were traded at the close of the day’s session.
In the last one week, shares of VectivBio Holding AG have increased by 0%.
VectivBio Holding AG's Key Ratios
VectivBio Holding AG has a market cap of $1.06 billion, indicating a price to book ratio of 3.6229 and a price to sales ratio of 21.079.
In the last 12-months VectivBio Holding AG’s revenue was $27.34 million with a gross profit of $27.34 million and an EBITDA of $-80416000. The EBITDA ratio measures VectivBio Holding AG's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, VectivBio Holding AG’s operating margin was -294.52% while its return on assets stood at -25.87% with a return of equity of -56.92%.
In Q1, VectivBio Holding AG’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
VectivBio Holding AG’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at $-2.1 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into VectivBio Holding AG’s profitability.
VectivBio Holding AG stock is trading at a EV to sales ratio of 14.3707 and a EV to EBITDA ratio of -5.2142. Its price to sales ratio in the trailing 12-months stood at 21.079.
VectivBio Holding AG stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $252.60 million
- Total Liabilities
- $24.74 million
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
VectivBio Holding AG ended 2023 with $252.60 million in total assets and $0 in total liabilities. Its intangible assets were valued at $252.60 million while shareholder equity stood at $213.37 million.
VectivBio Holding AG ended 2023 with $0 in deferred long-term liabilities, $24.74 million in other current liabilities, 3499000.00 in common stock, $-207765000.00 in retained earnings and $923000.00 in goodwill. Its cash balance stood at $221.42 million and cash and short-term investments were $221.42 million. The company’s total short-term debt was $137,000 while long-term debt stood at $0.
VectivBio Holding AG’s total current assets stands at $226.21 million while long-term investments were $0 and short-term investments were $4000.00. Its net receivables were $1.43 million compared to accounts payable of $1.80 million and inventory worth $-1434000.00.
In 2023, VectivBio Holding AG's operating cash flow was $0 while its capital expenditure stood at $42750.
Comparatively, VectivBio Holding AG paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
VectivBio Holding AG stock is currently trading at $16.85 per share. It touched a 52-week high of $16.98 and a 52-week low of $16.98. Analysts tracking the stock have a 12-month average target price of $18.
Its 50-day moving average was $15.52 and 200-day moving average was $10.14 The short ratio stood at 0.04 indicating a short percent outstanding of 0%.
Around 449.9% of the company’s stock are held by insiders while 8380.2% are held by institutions.
Frequently Asked Questions About VectivBio Holding AG
Similar Industry Stocks (Pharmaceuticals)
VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). VectivBio Holding AG was incorporated in 2019 and is headquartered in Basel, Switzerland. As of June 29, 2023, VectivBio Holding AG operates as a subsidiary of Ironwood Pharmaceuticals, Inc.